首页> 中文期刊> 《中国药业》 >雾化吸入糖皮质激素用于长期控制不佳的老年哮喘疗效分析

雾化吸入糖皮质激素用于长期控制不佳的老年哮喘疗效分析

         

摘要

目的 观察老年哮喘长期控制不佳应用雾化吸入糖皮质激素的疗效.方法 选取医院2014年7月至2016年7月收治的老年哮喘患者98例,随机分为试验组与对照组,各49例.试验组采用雾化吸入糖皮质激素治疗,对照组采用常规治疗,对比两组患者的疗效与不良反应.结果 试验组患者的呼气峰流速变化值明显优于对照组患者,差异有统计学意义(P<0.05);试验组患者哮喘控制测试(ACT)评分显著高于对照组患者,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异有统计学意义(P<0.05).结论 雾化吸入糖皮质激素治疗老年哮喘效果明显、安全性较高,值得临床推广.%Objective To analyze clinical efficacy of atomizing inhaled glucocorticoid in elderly patients with poor long-term asthma control. Methods Totally 98 elderly patients with asthma in our hospital from July 2014 to July 2016 were randomly divided into the experimental group and the control group,49 cases in each group. The experimental group was taken atomizing inhaled glucocorticoid,the control group was treated with conventional method. The therapeutic effect and adverse reactions in the two groups were compared. Results The peak expiratory flow rate of the experimental group was significantly better than that of the control group (P < 0. 05),the ACT scores of the experimental group was significantly higher than that of the control group ( P < 0. 05 ) ,the adverse reactions in the two groups had significant difference(P < 0. 05). Conclusion The clinical efficacy of atomizing inhaled glucocorticoid in elderly patients with poor long-term asthma control is good,it is safe and worthy of clinical promotion.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号